| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.01. | UK biotechs suffered restricted financing in 2025 | ||
| 26.01. | MSD ends takeover talks with Revolution Medicines | ||
| 26.01. | NICE greenlights Pfizer's Talzenna for NHS use | ||
| 23.01. | Corxel raises $287m as obesity continues to spark investor interest | ||
| 23.01. | Daiichi Sankyo and AstraZeneca's Enhertu gains NMPA approval for HER2 GEJ | ||
| 22.01. | BMS bets on Janux's novel solid tumour therapy through $850m deal | ||
| 22.01. | US set to officially exit WHO in culmination of Trump's domestic push | ||
| 22.01. | Heart disease and stroke deaths take a downturn, AHA report reveals | ||
| 22.01. | Johnson & Johnson reports 9.1% increase in sales for Q4 2025 | ||
| 22.01. | Opna Bio's OPN-2853 secures FDA's orphan drug status for myelofibrosis | ||
| 21.01. | Davos26: Trump says tariff threats helped fix US drug pricing 'unfairness' | ||
| 21.01. | Pfizer and Novavax ink $530m vaccine delivery licensing deal | ||
| 21.01. | BMS and Microsoft partner for AI-based lung cancer detection | ||
| 21.01. | Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies | ||
| 20.01. | Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up | ||
| 20.01. | GSK scoops up RAPT Therapeutics for $2.2bn | ||
| 20.01. | DeepHow introduces PharmaCloud for pharmaceutical manufacturers | ||
| 20.01. | iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson's | ||
| 19.01. | UK's pharma outlook buoyed by trans-Atlantic trade policies | ||
| 19.01. | Compounder sues Lilly and Novo for suppressing GLP-1RA competition | ||
| 19.01. | AstraZeneca to acquire China rights for AbelZeta's CAR-T therapy | ||
| 19.01. | FDA grants Novartis' ianalumab breakthrough therapy status for Sjögren's disease | ||
| 16.01. | FDA prevails over EMA in 2025 novel drug approvals | ||
| 16.01. | J&J's Caplyta doubles remission rate in MDD patients | ||
| 16.01. | UK's MHRA gives high-dose Wegovy the go-ahead in obesity |